ULTRAVATE (halobetasol propionate) by PharmaIN is signaling, immune function, inflammation, and protein regulation; however, the precise mechanism of action in plaque psoriasis is unknown. Approved for psoriasis. First approved in 1990.
Drug data last refreshed 10h ago · AI intelligence enriched 3w ago
ULTRAVATE is a topical cream containing halobetasol propionate, a potent corticosteroid approved in 1990 for treating plaque psoriasis. The drug works by modulating signaling, immune function, inflammation, and protein regulation, though its precise mechanism in psoriasis remains incompletely understood. It is administered topically as a cream formulation.
Product approaching loss of exclusivity with modest utilization signals a contracted brand team focused on legacy maintenance rather than expansion.
signaling, immune function, inflammation, and protein regulation; however, the precise mechanism of action in plaque psoriasis is unknown.
Combination of Halobetasol Propionate and Tazarotene Lotion (Duobrii®) for Palmoplantar Plaque Type Psoriasis
Safety and Efficacy of IDP-118 Lotion to Ultravate® in the Treatment of Plaque Psoriasis
Worked on ULTRAVATE at PharmaIN? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Working on ULTRAVATE offers limited career growth opportunity given its LOE-approaching status and minimal linked job openings; roles are primarily maintenance-focused with emphasis on defending legacy market share against generic and alternative competitors. Career progression on this product is constrained, making it suitable for consolidation or transition-planning rather than as a launching platform for advancement.
Upgrade to Pro to access Medicare Part D spending data and other premium pharma intelligence.
Upgrade to Pro — $25/mo